{"success":true,"data":{"pressRelease":{"id":"145172","rtpr_id":"nGNX3FR8Q7-20260916","ticker":"AMIX","exchange":"NASDAQ","all_tickers":["AMIX"],"title":"Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors","author":"Globe Newswire","published_at":"2026-09-16T12:30:00.356Z","article_body":"Appointment adds more than four decades of MedTech leadership, FDA regulatory\nand strategic transaction experience, including work supporting renal\ndenervation and other category-defining technologies\n\nTHE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc.\n(https://www.globenewswire.com/Tracker?data=vvSWe5bFKIelOHc01E5ZAvtpvgbwclECq6aEtTOKRG1ak7exIyUVrbNrPIaAAZV38dq3D4Zx2Tp618VlJAGCESPybayRLj67unqImQIZaWdJnAa6OKq-dTy6x5KAGzoxTcYdke52TJk3LKV7A4vxSDcRQt19sw2joiXZRXfSfqRRb7tjplIxed-dlbPM7Vt5BxCJw5Fx6rXgkam4UNv32QqF7pwkv-vdPT3n-fLkRVJMy5M0ffdaaMOauoq2I1uQKLCpXu5mU_C6cPGgHF0EFQ==) (NASDAQ:\nAMIX) (“Autonomix” or the “Company”), a medical device company\ndedicated to advancing precision nerve-targeted treatments, today announced\nthe appointment of Sandra Cohen Kalter, former Vice President and Chief\nRegulatory Counsel of Medtronic plc (Medtronic) as a Board Member for\nAutonomix.\n\n\n\nMs. Kalter brings more than four decades of experience across the medical\ndevice and healthcare industries, including extensive senior-level experience\nat Medtronic, one of the world’s largest and most diversified medical\ntechnology companies. During her tenure at Medtronic, she played a key role in\nregulatory, clinical and strategic initiatives spanning multiple business\nunits and oversaw due diligence and integration activities associated with\nmore than 27 acquisitions.\n\nHer Medtronic experience includes supporting some of the company’s most\nsignificant and innovative technologies, including the Symplicity Spyral(™)\nRenal Denervation system, Evolut(™) TAVR platform, Micra(™) Transcatheter\nPacing System, and PulseSelect(™) Pulsed Field Ablation system. Her\nexperience also includes involvement with the acquisition and integration of\ntechnologies that contributed to Medtronic’s expansion of its renal\ndenervation platforms and electrophysiology.\n\n“Sandy brings an extraordinary level of MedTech experience to Autonomix,\nparticularly from her time at Medtronic, where she was at the intersection of\nregulatory strategy, clinical development, technology evaluation and corporate\ntransactions,” said Walter Klemp, Chairman of the Board of Autonomix. “Her\nfirsthand understanding of how a global medical device leader evaluates\nemerging technologies, navigates regulatory pathways and approaches strategic\npartnerships and acquisitions is exceptionally valuable to Autonomix as we\nadvance our technology and expand our relationships across the industry.”\n\nAs a Board Member, Ms. Kalter will provide strategic guidance to Autonomix’s\nBoard and management team as the Company advances its proprietary technologies\nand evaluates opportunities to expand its technology across additional\ntherapeutic applications. Her experience is also expected to support the\nCompany’s strategic discussions with potential industry partners and other\nstakeholders as Autonomix continues to develop its platform.\n\n“I am excited to join Autonomix as a Board Member at an important stage in\nthe Company’s development,” said Sandra Cohen Kalter. “Having spent much\nof my career at Medtronic helping guide innovative technologies through\ncomplex regulatory, clinical and strategic processes, I understand the\nimportance of combining strong technology with a thoughtful development and\ncommercialization strategy. Autonomix has developed a differentiated approach\nto nerve sensing and targeted therapy, leveraging advanced technology to\npotentially revolutionize how clinicians detect, interpret and treat\nnerve-related conditions. I believe Autonomix is well positioned to advance\nthis technology toward clinical development and unlock its broader potential\nacross the medical device landscape. I look forward to working with the Board\nand management team as the Company moves this important technology forward.”\n\nExtensive Medtronic Experience\n\nDuring her 20 years at Medtronic, Ms. Kalter served in senior legal regulatory\nleadership roles, including Vice President and Chief Regulatory Counsel,\nadvising Medtronic business units on FDA strategy, clinical and legal\nregulatory matters, quality systems, product development and\ncommercialization.\n\nHer Medtronic experience includes:\n* More than 27 acquisitions: Oversaw due diligence and integration activities\nfor more than 27 acquisitions, including technologies that expanded\nMedtronic’s capabilities in renal denervation, electrophysiology and other\nareas of medical technology.\n* Category-defining technologies: Regulatory and strategic involvement with\nmajor Medtronic platforms including Symplicity Spyral(™) Renal Denervation,\nEvolut(™) TAVR, Micra(™) Transcatheter Pacing System and PulseSelect(™)\nPFA.\n* FDA and legal regulatory leadership: Built and managed an in-house FDA legal\nteam supporting Medtronic’s business units and helping guide legal\nregulatory strategies for innovative medical technologies.\n* Strategic technology evaluation: Extensive experience evaluating emerging\nmedical technologies and navigating the regulatory, clinical and strategic\nconsiderations involved in bringing innovative devices into major medical\ndevice portfolios.\nPrior to joining Medtronic, Ms. Kalter spent 13 years as FDA/Healthcare\nCounsel at King & Spalding LLP, where she advised clients on complex FDA\nregulatory matters, including regulatory filings and FDA advisory panel\nproceedings.\n\n“Sandy’s experience is particularly relevant to where Autonomix is\nheaded,” commented Brad Hauser, Chief Executive Officer of Autonomix. “We\nare developing technology at the intersection of sensing, neuromodulation and\nminimally invasive intervention, and her experience with major platforms in\nrenal denervation and electrophysiology gives her a unique perspective on the\nopportunity in front of us. We are thrilled to have her strategic insight as\nwe work to advance Autonomix toward clinical development and ultimately\nposition the Company for broader industry partnerships.”\n\nMs. Kalter received a Juris Doctor degree from The George Washington\nUniversity National Law Center and a Bachelor of Science in Journalism from\nNorthwestern University.\n\nAbout Autonomix Medical, Inc. \n\nAutonomix is a medical device company focused on advancing innovative\ntechnologies to revolutionize how diseases involving the nervous system are\ndiagnosed and treated. The Company’s first-in-class platform system\ntechnology includes a catheter-based microchip sensing array that may have the\nability to detect and differentiate neural signals with greater sensitivity\nthan currently available technologies. We believe this will enable, for the\nfirst time ever, transvascular diagnosis and treatment of diseases involving\nthe peripheral nervous system virtually anywhere in the body.\n\nOur technology constitutes a platform to address dozens of potential\nindications, including cardiology, hypertension and chronic pain management,\nacross a wide disease spectrum. Our technology is investigational and has not\nyet been cleared for marketing in the United States.\n\nFor more information, visit autonomix.com\n(https://www.globenewswire.com/Tracker?data=oomJf2YgxID8jsteVa1w5G8r0lc8A-IkGCbxGQXe31UPDzq2E4b2cerwey0LsXc6TbxqWZNOds4epaltUazJ0g==) and\nconnect with the Company on X\n(https://www.globenewswire.com/Tracker?data=mibxTmOVDq9A0QOQLt0E4zDZhY6-rSV712M7uyTFP12FXkwEyXyNi9WDHAhozn75U_XFcv99y71N2wkJB-0rvg==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=2UHRaW5vdP1lpUUhoETJkp44AftE2TKUqpejUJn1_qlGNAc_Vk3w9fDgsZ7DLW5Sk1eJ8cnmhYbLydLdTWY2dnL7EJ784q4wQzp-jz3prHLSwy4H1miyXq6lP41LBSTV), Instagram\n(https://www.globenewswire.com/Tracker?data=pmya1Zw4-nLHfOAqLU9YlmCahvwPIVo3d5jxFJ4HzaeVWmvubQjd59P_4coPo2FdEgOGGM_LOP8nYWOkblwheNreoscH6uGCzEDQ0nNpgaU=) and Facebook\n(https://www.globenewswire.com/Tracker?data=Pl_D6hhC4AZgAp7Q4pt-41UyN4Pqxos60eXAvpAPuaiCTckjLPoCIdsdlteXOASfhZmLq4NDnkaClXZ_46tb9e2tZtSl1CXBg88NNp7vUloQ4uICNtIPJ3j0QsN_Cs20).\n\nForward Looking Statements \n\nSome of the statements in this release are “forward-looking statements,”\nwhich involve risks and uncertainties. Such forward-looking statements can be\nidentified by the use of words such as “should,” “might,” “may,”\n“intends,” “anticipates,” “believes,” “estimates,”\n“projects,” “forecasts,” “expects,” “plans,” and\n“proposes.” Forward-looking statements in this press release include, but\nare not limited to, expectations regarding the potential effectiveness and\nclinical benefits of Autonomix’s nerve-targeted treatments for pancreatic\ncancer pain and other conditions, the versatility and scalability of the\nCompany’s platform technology, the potential for future clinical\napplications across multiple organ systems, the strength and scope of the\nCompany’s intellectual property portfolio, and the potential for the\nCompany’s patented technologies to support patient selection, procedural\nguidance and post-treatment monitoring across multiple neuromodulation\napplications.\n\nAlthough Autonomix believes that the expectations reflected in these\nforward-looking statements are based on reasonable assumptions, there are a\nnumber of risks and uncertainties that could cause actual results to differ\nmaterially from such forward-looking statements. You are urged to carefully\nreview and consider any cautionary statements and other disclosures, including\nthe statements made under the heading “Risk Factors” and elsewhere in the\nmost recent Annual Report on Form 10-K filed with the U.S. Securities and\nExchange Commission (SEC) on May 27, 2026, and from time to time, our other\nfilings with the SEC. Forward-looking statements speak only as of the date of\nthis press release and Autonomix does not undertake any duty to update any\nforward-looking statements except as may be required by law.\n\nInvestor and Media Contact \n\nJTC Team, LLC\nJenene Thomas\n908.824.0775\nautonomix@jtcir.com\n\nAttachment\n*     Autonomix Medical, Inc.\n(https://ml.globenewswire.com/Resource/Download/e4c56b80-ba6c-47c0-8882-cab1cbe71f32)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8b0ba1bc-43b1-4445-b895-712da30f7df8)\nAutonomix Medical, Inc. \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e4c56b80-ba6c-47c0-8882-cab1cbe71f32/en)\nAutonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra\nCohen Kalter to Board of Directors\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3FR8Q7-20260916","title":"Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors","author":"Globe Newswire","ticker":"AMIX","created":"2026-09-16T12:30:00.356Z","tickers":["AMIX"],"exchange":"NASDAQ","article_body":"Appointment adds more than four decades of MedTech leadership, FDA regulatory\nand strategic transaction experience, including work supporting renal\ndenervation and other category-defining technologies\n\nTHE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc.\n(https://www.globenewswire.com/Tracker?data=vvSWe5bFKIelOHc01E5ZAvtpvgbwclECq6aEtTOKRG1ak7exIyUVrbNrPIaAAZV38dq3D4Zx2Tp618VlJAGCESPybayRLj67unqImQIZaWdJnAa6OKq-dTy6x5KAGzoxTcYdke52TJk3LKV7A4vxSDcRQt19sw2joiXZRXfSfqRRb7tjplIxed-dlbPM7Vt5BxCJw5Fx6rXgkam4UNv32QqF7pwkv-vdPT3n-fLkRVJMy5M0ffdaaMOauoq2I1uQKLCpXu5mU_C6cPGgHF0EFQ==) (NASDAQ:\nAMIX) (“Autonomix” or the “Company”), a medical device company\ndedicated to advancing precision nerve-targeted treatments, today announced\nthe appointment of Sandra Cohen Kalter, former Vice President and Chief\nRegulatory Counsel of Medtronic plc (Medtronic) as a Board Member for\nAutonomix.\n\n\n\nMs. Kalter brings more than four decades of experience across the medical\ndevice and healthcare industries, including extensive senior-level experience\nat Medtronic, one of the world’s largest and most diversified medical\ntechnology companies. During her tenure at Medtronic, she played a key role in\nregulatory, clinical and strategic initiatives spanning multiple business\nunits and oversaw due diligence and integration activities associated with\nmore than 27 acquisitions.\n\nHer Medtronic experience includes supporting some of the company’s most\nsignificant and innovative technologies, including the Symplicity Spyral(™)\nRenal Denervation system, Evolut(™) TAVR platform, Micra(™) Transcatheter\nPacing System, and PulseSelect(™) Pulsed Field Ablation system. Her\nexperience also includes involvement with the acquisition and integration of\ntechnologies that contributed to Medtronic’s expansion of its renal\ndenervation platforms and electrophysiology.\n\n“Sandy brings an extraordinary level of MedTech experience to Autonomix,\nparticularly from her time at Medtronic, where she was at the intersection of\nregulatory strategy, clinical development, technology evaluation and corporate\ntransactions,” said Walter Klemp, Chairman of the Board of Autonomix. “Her\nfirsthand understanding of how a global medical device leader evaluates\nemerging technologies, navigates regulatory pathways and approaches strategic\npartnerships and acquisitions is exceptionally valuable to Autonomix as we\nadvance our technology and expand our relationships across the industry.”\n\nAs a Board Member, Ms. Kalter will provide strategic guidance to Autonomix’s\nBoard and management team as the Company advances its proprietary technologies\nand evaluates opportunities to expand its technology across additional\ntherapeutic applications. Her experience is also expected to support the\nCompany’s strategic discussions with potential industry partners and other\nstakeholders as Autonomix continues to develop its platform.\n\n“I am excited to join Autonomix as a Board Member at an important stage in\nthe Company’s development,” said Sandra Cohen Kalter. “Having spent much\nof my career at Medtronic helping guide innovative technologies through\ncomplex regulatory, clinical and strategic processes, I understand the\nimportance of combining strong technology with a thoughtful development and\ncommercialization strategy. Autonomix has developed a differentiated approach\nto nerve sensing and targeted therapy, leveraging advanced technology to\npotentially revolutionize how clinicians detect, interpret and treat\nnerve-related conditions. I believe Autonomix is well positioned to advance\nthis technology toward clinical development and unlock its broader potential\nacross the medical device landscape. I look forward to working with the Board\nand management team as the Company moves this important technology forward.”\n\nExtensive Medtronic Experience\n\nDuring her 20 years at Medtronic, Ms. Kalter served in senior legal regulatory\nleadership roles, including Vice President and Chief Regulatory Counsel,\nadvising Medtronic business units on FDA strategy, clinical and legal\nregulatory matters, quality systems, product development and\ncommercialization.\n\nHer Medtronic experience includes:\n* More than 27 acquisitions: Oversaw due diligence and integration activities\nfor more than 27 acquisitions, including technologies that expanded\nMedtronic’s capabilities in renal denervation, electrophysiology and other\nareas of medical technology.\n* Category-defining technologies: Regulatory and strategic involvement with\nmajor Medtronic platforms including Symplicity Spyral(™) Renal Denervation,\nEvolut(™) TAVR, Micra(™) Transcatheter Pacing System and PulseSelect(™)\nPFA.\n* FDA and legal regulatory leadership: Built and managed an in-house FDA legal\nteam supporting Medtronic’s business units and helping guide legal\nregulatory strategies for innovative medical technologies.\n* Strategic technology evaluation: Extensive experience evaluating emerging\nmedical technologies and navigating the regulatory, clinical and strategic\nconsiderations involved in bringing innovative devices into major medical\ndevice portfolios.\nPrior to joining Medtronic, Ms. Kalter spent 13 years as FDA/Healthcare\nCounsel at King & Spalding LLP, where she advised clients on complex FDA\nregulatory matters, including regulatory filings and FDA advisory panel\nproceedings.\n\n“Sandy’s experience is particularly relevant to where Autonomix is\nheaded,” commented Brad Hauser, Chief Executive Officer of Autonomix. “We\nare developing technology at the intersection of sensing, neuromodulation and\nminimally invasive intervention, and her experience with major platforms in\nrenal denervation and electrophysiology gives her a unique perspective on the\nopportunity in front of us. We are thrilled to have her strategic insight as\nwe work to advance Autonomix toward clinical development and ultimately\nposition the Company for broader industry partnerships.”\n\nMs. Kalter received a Juris Doctor degree from The George Washington\nUniversity National Law Center and a Bachelor of Science in Journalism from\nNorthwestern University.\n\nAbout Autonomix Medical, Inc. \n\nAutonomix is a medical device company focused on advancing innovative\ntechnologies to revolutionize how diseases involving the nervous system are\ndiagnosed and treated. The Company’s first-in-class platform system\ntechnology includes a catheter-based microchip sensing array that may have the\nability to detect and differentiate neural signals with greater sensitivity\nthan currently available technologies. We believe this will enable, for the\nfirst time ever, transvascular diagnosis and treatment of diseases involving\nthe peripheral nervous system virtually anywhere in the body.\n\nOur technology constitutes a platform to address dozens of potential\nindications, including cardiology, hypertension and chronic pain management,\nacross a wide disease spectrum. Our technology is investigational and has not\nyet been cleared for marketing in the United States.\n\nFor more information, visit autonomix.com\n(https://www.globenewswire.com/Tracker?data=oomJf2YgxID8jsteVa1w5G8r0lc8A-IkGCbxGQXe31UPDzq2E4b2cerwey0LsXc6TbxqWZNOds4epaltUazJ0g==) and\nconnect with the Company on X\n(https://www.globenewswire.com/Tracker?data=mibxTmOVDq9A0QOQLt0E4zDZhY6-rSV712M7uyTFP12FXkwEyXyNi9WDHAhozn75U_XFcv99y71N2wkJB-0rvg==), LinkedIn\n(https://www.globenewswire.com/Tracker?data=2UHRaW5vdP1lpUUhoETJkp44AftE2TKUqpejUJn1_qlGNAc_Vk3w9fDgsZ7DLW5Sk1eJ8cnmhYbLydLdTWY2dnL7EJ784q4wQzp-jz3prHLSwy4H1miyXq6lP41LBSTV), Instagram\n(https://www.globenewswire.com/Tracker?data=pmya1Zw4-nLHfOAqLU9YlmCahvwPIVo3d5jxFJ4HzaeVWmvubQjd59P_4coPo2FdEgOGGM_LOP8nYWOkblwheNreoscH6uGCzEDQ0nNpgaU=) and Facebook\n(https://www.globenewswire.com/Tracker?data=Pl_D6hhC4AZgAp7Q4pt-41UyN4Pqxos60eXAvpAPuaiCTckjLPoCIdsdlteXOASfhZmLq4NDnkaClXZ_46tb9e2tZtSl1CXBg88NNp7vUloQ4uICNtIPJ3j0QsN_Cs20).\n\nForward Looking Statements \n\nSome of the statements in this release are “forward-looking statements,”\nwhich involve risks and uncertainties. Such forward-looking statements can be\nidentified by the use of words such as “should,” “might,” “may,”\n“intends,” “anticipates,” “believes,” “estimates,”\n“projects,” “forecasts,” “expects,” “plans,” and\n“proposes.” Forward-looking statements in this press release include, but\nare not limited to, expectations regarding the potential effectiveness and\nclinical benefits of Autonomix’s nerve-targeted treatments for pancreatic\ncancer pain and other conditions, the versatility and scalability of the\nCompany’s platform technology, the potential for future clinical\napplications across multiple organ systems, the strength and scope of the\nCompany’s intellectual property portfolio, and the potential for the\nCompany’s patented technologies to support patient selection, procedural\nguidance and post-treatment monitoring across multiple neuromodulation\napplications.\n\nAlthough Autonomix believes that the expectations reflected in these\nforward-looking statements are based on reasonable assumptions, there are a\nnumber of risks and uncertainties that could cause actual results to differ\nmaterially from such forward-looking statements. You are urged to carefully\nreview and consider any cautionary statements and other disclosures, including\nthe statements made under the heading “Risk Factors” and elsewhere in the\nmost recent Annual Report on Form 10-K filed with the U.S. Securities and\nExchange Commission (SEC) on May 27, 2026, and from time to time, our other\nfilings with the SEC. Forward-looking statements speak only as of the date of\nthis press release and Autonomix does not undertake any duty to update any\nforward-looking statements except as may be required by law.\n\nInvestor and Media Contact \n\nJTC Team, LLC\nJenene Thomas\n908.824.0775\nautonomix@jtcir.com\n\nAttachment\n*     Autonomix Medical, Inc.\n(https://ml.globenewswire.com/Resource/Download/e4c56b80-ba6c-47c0-8882-cab1cbe71f32)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/8b0ba1bc-43b1-4445-b895-712da30f7df8)\nAutonomix Medical, Inc. \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e4c56b80-ba6c-47c0-8882-cab1cbe71f32/en)\nAutonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra\nCohen Kalter to Board of Directors\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-16T12:30:00.682053122Z","server_sent_at_ms":1789561800682},"received_at":"2026-09-16T12:30:00.740Z","source_url":null},"analysis":{"id":"133994","press_release_id":"145172","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Autonomix's core technology is investigational and has not been cleared for marketing in the United States"],"eventType":"board_change","narrative":"Autonomix Medical appointed Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic, to its board of directors.\n\nKalter brings more than four decades of medtech regulatory and transaction experience, including overseeing due diligence and integration for more than 27 Medtronic acquisitions and supporting platforms such as Symplicity Spyral renal denervation, Evolut TAVR, Micra pacing and PulseSelect PFA.\n\nManagement expects her FDA regulatory and partnership experience to support Autonomix's push toward clinical development and strategic discussions with potential industry partners; the company's nerve-sensing platform remains investigational and is not yet cleared for marketing in the U.S.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Former Medtronic chief regulatory counsel joins AMIX board, adding FDA and M&A depth ahead of clinical development and potential partnerships."},"keyFigures":{"customDimensions":{"experience_years":"more than four decades","acquisitions_overseen":"more than 27","medtronic_tenure_years":20,"king_spalding_tenure_years":13}},"quotedText":"Sandy brings an extraordinary level of MedTech experience to Autonomix","namedEntities":{"people":[{"name":"Sandra Cohen Kalter","role":"New Board Member; former Vice President and Chief Regulatory Counsel of Medtronic"},{"name":"Walter Klemp","role":"Chairman of the Board, Autonomix"},{"name":"Brad Hauser","role":"CEO, Autonomix"}],"products":["Symplicity Spyral Renal Denervation system","Evolut TAVR platform","Micra Transcatheter Pacing System","PulseSelect Pulsed Field Ablation system","Autonomix catheter-based microchip sensing array"],"companies":[{"name":"Autonomix Medical, Inc.","ticker":"AMIX","relationship":"filer"},{"name":"Medtronic plc","relationship":"former employer of new board member"},{"name":"King & Spalding LLP","relationship":"prior law firm of new board member"},{"name":"JTC Team, LLC","relationship":"investor relations contact"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine board appointment, but the addition of a former Medtronic Chief Regulatory Counsel with deep FDA and M&A experience is a modest positive signal for a pre-commercial medical device company. No financial or operational impact disclosed."},"tickerRelevance":{"others":[],"primary":"AMIX"},"globalImportance":12,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-board-appointment","sectorWeight":"medtech","credentialQuality":"notable (ex-Medtronic Chief Regulatory Counsel)","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"board_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Autonomix Medical appointed Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic, to its board of directors.\n\nKalter brings more than four decades of medtech regulatory and transaction experience, including overseeing due diligence and integration for more than 27 Medtronic acquisitions and supporting platforms such as Symplicity Spyral renal denervation, Evolut TAVR, Micra pacing and PulseSelect PFA.\n\nManagement expects her FDA regulatory and partnership experience to support Autonomix's push toward clinical development and strategic discussions with potential industry partners; the company's nerve-sensing platform remains investigational and is not yet cleared for marketing in the U.S.","key_figures":{"customDimensions":{"experience_years":"more than four decades","acquisitions_overseen":"more than 27","medtronic_tenure_years":20,"king_spalding_tenure_years":13}},"named_entities":{"people":[{"name":"Sandra Cohen Kalter","role":"New Board Member; former Vice President and Chief Regulatory Counsel of Medtronic"},{"name":"Walter Klemp","role":"Chairman of the Board, Autonomix"},{"name":"Brad Hauser","role":"CEO, Autonomix"}],"products":["Symplicity Spyral Renal Denervation system","Evolut TAVR platform","Micra Transcatheter Pacing System","PulseSelect Pulsed Field Ablation system","Autonomix catheter-based microchip sensing array"],"companies":[{"name":"Autonomix Medical, Inc.","ticker":"AMIX","relationship":"filer"},{"name":"Medtronic plc","relationship":"former employer of new board member"},{"name":"King & Spalding LLP","relationship":"prior law firm of new board member"},{"name":"JTC Team, LLC","relationship":"investor relations contact"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T12:30:33.054Z","global_importance":12,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-board-appointment","sectorWeight":"medtech","credentialQuality":"notable (ex-Medtronic Chief Regulatory Counsel)","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":32305,"modelName":"glm-5.3-flash"}}